Skip to content

    Indo Us Biotech Limited

    Fast Moving Consumer Goods
    Fast Moving Consumer Goods

    Overview

    Price

    Market Cap

    ₹173 Cr

    Sector

    Fast Moving Consumer Goods

    Fast Moving Consumer Goods

    Rank

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital6691020202020
    Reserves1015304443586772
    Borrowings911121214152837
    Other Liabilities1011437434
    Total Liabilities354456698498117133
    AssetsFixed Assets12677101011
    CWIP12214000
    Investments00000000
    Other Assets323948617488108121
    Total Assets354456698498117133

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25FY26
    ActivitiesCash from Operating-3-103121-13
    Cash from Investing-3-1-2-5-7-3-1-2
    Cash from Financing621261-120
    SummaryCapital Expenditure
    Free Cash Flow-4-1-2-1-101-15
    FCF Margin

    Valuation

    Assumptions

    Current — INDOUS
    Price
    ₹87
    EPS (TTM)
    ₹6.54
    PE (TTM)
    13.3
    Profit growth
    21.9%

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (17.4×) and current (13.3×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹87
    vs
    Fair value · 15% return
    ₹104
    19%Undervalued

    At 21.9% growth and a 13× exit, ₹87 only delivers your return if you pay ₹104. The price is currently baking in 18% growth.

    EPS grows 21.9%/yr for 5 years, then fades to 6% over 2, exits at 13×.

    YearGrowthEPS (₹)
    FY2721.9%7.97
    FY2821.9%9.72
    FY2921.9%11.85
    FY3021.9%14.44
    FY3121.9%17.60
    FY3213.9% ·fade20.06
    FY336.0% ·fade21.26

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Indo Us Biotech Limited

    Guides on how to read this kind of business and the numbers that matter.